Patent Grant
10035956
The disclosure relates to a compound and a liquid-crystal composition employing the same.
In recent years, compounds having a terminal reactive functional group are generally used in the elements (such as a liquid-crystal composition or an optical film) of a liquid-crystal display. For example, a compound having a terminal reactive functional group may be employed in the manufacture of a cholesteric liquid-crystal composition, a brightness enhancement film, or an alignment film. Due to the different chemical structures, conventional compounds having a terminal reactive functional group, however, have low solubility in the liquid-crystal host, resulting in a poor film-forming ability being exhibited by liquid-crystal compositions that employ conventional compounds with a terminal reactive functional group.
An embodiment of the disclosure provides a compound, wherein the compound has a structure represented by Formula (I):
wherein Za and Zb are independently
A1 and A2 are independently
A3 and A4 are independently single bond,
Z1, Z2, Z3, and Z4 are independently single bond,
R is independently hydrogen, or C1-4 alkyl group; R1 and R2 are independently single bond, —O—(CH2)n—, —CH═CH—(CH2)2—, —(CH2)2—CH═CH—, —CH═CH—, or —C≡C—; n is an integer from 1 to 6; B1 and B2 are independently
and, R3 is hydrogen, or methyl group.
According to another embodiment of the disclosure, the disclosure also provides a liquid-crystal composition including 100 parts by weight of liquid-crystal host; and 0.1-30 parts by weight of the aforementioned compound.
The disclosure provides a compound and a liquid-crystal composition employing the same. Due to the specific chemical structure, the compound of the disclosure exhibits high helical twisting power (HTP), high solubility in the liquid-crystal host, stable temperature dependence, narrow wavelength variation range, and accurately adjusts the reflective wavelength of cholesteric liquid-crystal, and enhances the stability of cholesteric liquid-crystal. Therefore, the cholesteric liquid-crystal employing the compound has wide application.
According to embodiments of the disclosure, the compound of the disclosure can have a structure of Formula (I):
wherein Za and Zb are independently
A1 and A2 are independently
A3 and A4 are independently single bond,
Z1, Z2, Z3, and Z4 are independently single bond,
R is independently hydrogen, or C1-4 alkyl group; R1 and R2 are independently single bond, —O—(CH2)n—, —CH═CH—(CH2)2—, —(CH2)2—CH═CH—, —CH═CH—, or —C≡C—; n is an integer from 1 to 6; B1 and B2 are independently
and, R3 is hydrogen, or methyl group. The biindane moiety of the compound represented by Formula (I) can be S-form or R-form.
According to embodiments of the disclosure, the compound of the disclosure can have a carbonate ester moiety
for bonding a side chain. For example, the compound can have a structure of Formula (II)
wherein A1, A2, A3, A4, Z1, Z2, Z3, Z4R, R1, R2, B1, and B2 are as previously defined. For example, the compound can be
The biindane moiety of the compound represented by Formula (II) can be S-form or R-form.
According to embodiments of the disclosure, the compound of the disclosure can have a structure of Formula (III):
wherein A1, A2, A3, A4, Z1, Z2, Z3, Z4, R, R1, R2, B1, and B2 are as previously defined. For example, the compound can be
The biindane moiety of the compound represented by Formula (III) can be S-form or R-form.
According to embodiments of the disclosure, the compound of the disclosure can have a structure of Formula (IV) or (V):
wherein A1, A2, A3, A4, Z1, Z2Z3, Z4, R, R1, R2, B1, and B2 are as previously defined. For example, the compound can be
The biindane moiety of the compound represented by Formula (IV) or Formula (V) can be S-form or R-form.
According to other embodiments of the disclosure, the compound of the disclosure can have a structure of Formula (VI) or (VII):
wherein A1, A2, A3, A4, Z1, Z2, Z3, Z4, R, R1, R2, B1, and B2 are as previously defined. For example, the compound can be
The biindane moiety of the compound represented by Formula (VI) or Formula (VII) can be S-form or R-form.
According to embodiments of the disclosure, the disclosure provides a liquid-crystal composition. The liquid-crystal composition includes (a) 100 parts by weight of a liquid-crystal host; and (b) 0.1-50 parts by weight of a compound having Formula (I). For example, the compound having Formula (I) is present in an amount from 0.1 to 30 parts by weight or from 0.1 to 25 parts by weight.
The compound of the disclosure can serve as a chiral additive and add into nematic liquid-crystal, smectic liquid-crystal, or discotic liquid-crystal. In one embodiment, the compound of the disclosure can mix with nematic liquid-crystal to form a cholesteric liquid-crystal composition used in phototunable liquid-crystal display devices.
The liquid-crystal host can be a compound with or without a polymerizable group. In addition, the liquid-crystal composition of the disclosure can optionally include a polymerizable monomer, a polymerization initiator, a binder resin, a solvent, a surfactant, a tackifying agent, a polymerization inhibitor, an ultraviolet absorber, or other chiral additives. According to embodiments of the disclosure, the polymerizable monomer can be a compound with unsaturated double bond such as: pentaerythritol tetraacrylate, dipentaerythritol hexaacrylate, or derivatives thereof. The polymerization initiator can be p-methoxyphenyl-2,4-bis(trichloromethyl)-s-triazine, 4,4′-bis(N,N-dimethylamino) benzophenone, benzyldimethylketal, or thioxanthone amine. The binder resin can be polystyrene compound (such as polystyrene, or poly-α-methyl styrene), cellulose resins (such as methyl cellulose, ethyl cellulose, or acetyl cellulose), or acetal resin (such as polyvinyl formal, or polyvinyl butyral). The surfactant can be a nonionic surfactant. In order to increase the storability of the liquid-crystal composition, the liquid-crystal composition can include the polymerization inhibitor. The polymerization inhibitor can be hydroquinone, hydroquinone monomethyl ether, phenothiazine, or benzoquinone. The solvent can be 2-butanone, cyclohexanone, dichloromethane, or chloroform
According to embodiments of the disclosure, since the compound has carbonate ester moiety
for bonding a side chain, the compound can exhibit high helical twisting power (HTP), improved voltage holding ratio, high solubility in the liquid-crystal host, and long precipitation time under low temperature.
Below, exemplary embodiments will be described in detail so as to be easily realized by a person having ordinary knowledge in the art.
Preparation of Compound
10 g of Compound 1 (0.038 mol) was added into a reaction bottle. Next, 20 mL of thionyl chloride (SOCl2) was added into the reaction bottle, and the reaction bottle was heated to reflux at 80° C. After Compound 1 was completely dissolved in thionyl chloride, the reaction bottle was still heated to reflux for 30 minutes. Next, after cooling to room temperature (25), thionyl chloride (SOCl2) was removed completely. 40 mL of tetrahydrofuran (THF) was added into the reaction bottle in an ice bath (0° C.), obtaining a first solution. Next, 8.88 g of 1,4-cyclohexanediol (0.076 mol), 7.68 g of triethylamine (0.076 mol), 0.93 g of 4-dimethylaminopyridine (DMAP) (0.0076 mo , and 50 mL of tetrahydrofuran (THF) were added into another reaction bottle, obtaining a second solution. Next, the first solution was added dropwisely into the second solution in an ice bath (0° C.). After the addition was complete, the mixture was stirred in an ice bath (0° C.) for 30 minutes, and then stirred at room temperature (25° C.) for 1 hour. Next, after removing tetrahydrofuran (THF), 100 mL of dichloromethane (CH2Cl2) was added. After subjecting it to an ultrasonic vibration treatment for 30 minutes, 50 mL of hydrochloric acid aqueous solution (5 wt %) was mixed with the mixture. After extraction, an organic phase was separated, and then dried by anhydrous magnesium sulfate. After concentration, the result was dissolved in 10 mL of tetrahydrofuran (THF). Next, 200 mL of methanol was added, and then a solid was deposited. After removing the solid by filtration, the filtrate was collected. After concentration, Compound 2 (maroon liquid) was obtained with a yield of 55%. The synthesis pathway of the above reaction was as follows:
Next, 8.0 g of compound 2 (0.022 mol), 0.6 g of pyridine, and 40 mL of dichloromethane (CH2Cl2) was added into a reaction bottle. Next, 2 g of triphosgene (dissolved in 10 mL of dichloromethane) was added slowly into the reaction bottle in an ice bath (0° C.). After stirring for 1 hour, a third solution was obtained. Next, 1.5 g of compound 3 (
S-form) (0.006 mol), 0.6 g of triethylamine (0.006 mol), 0.01 g of 4-dimethylaminopyridine (DMAP) (0.0006 mol), and 50 mL of tetrahydrofuran (THF) was added into another reaction bottle, obtaining a fourth solution. Next, the third solution was added dropwisely into the fourth solution in an ice bath (0° C.). After the addition was complete, the mixture was stirred in an ice bath (0° C.) for 30 minutes and then stirred at room temperature (25° C.) for 1 hour. Next, after removing tetrahydrofuran (THF), 100 mL of dichloromethane (CH2Cl2) was added. After subjecting it to an ultrasonic vibration treatment for 30 minutes, 50 mL of hydrochloric acid aqueous solution (5 wt %) was added. After extraction, an organic phase was separated, and then dried by anhydrous magnesium sulfate. After concentration, 10 mL of tetrahydrofuran (THF) was added. Next, 200 mL of methanol was added, and then a solid was deposited. After removing the solid by filtration, the filtrate was collected. After concentration, Chiral Compound 1 was obtained with a yield of 51%. The synthesis pathway of the above reaction was as follows:
Chiral Compound 1 was analyzed by nuclear magnetic resonance (NMR) spectroscopy and the result is as follows: 1H NMR (300 MHz, CDCl3): 1.27-1.31(m, 8H), 1.43(s, 8H), 1.91(s 8H), 2.30-2.38(m,4H), 3.1(d, J=2.75 Hz, 4H),4.06(d, J=4.4 Hz, 4H), 4.25-4.27(d, J=5.6 Hz, 4H) 4.52(m,2H), 5.02(m, 2H), 5.83-5.85(d, J=10.3 Hz, 2H), 6.11-6.16(dd, J=8.4,10.4 Hz 2H), 6.40-6.44(d, J=17.34 Hz, 2H), 6.90-6.92(d, J=8.6 Hz, 4H), 7.00-7.02(d, J=7.9 Hz, 2H), 7.15-7.17(d, J=8.1 Hz, 2H), 7.23-7.25(d, J=8.0 Hz, 2H), 7.97-7.98(d, J=8.5Hz, 4H)
10 g of compound 1 (0.038 mol) was added into a reaction bottle. Next, 20 mL of thionyl chloride (SOCl2) was added into the reaction bottle, and the reaction bottle was heated to reflux at 80° C. . After Compound 1 was completely dissolved in thionyl chloride, the reaction bottle was still heated to reflux for 30 minutes. Next, after cooling to room temperature (25), thionyl chloride (SOCl2) was removed completely. 40 mL of tetrahydrofuran (THF) was added into the reaction bottle in an ice bath (0° C.), obtaining a first solution. Next, 8.33 g of hydroquinone (0.076 mol), 7.68 g of triethylamine (0.076 mol), 0.93 g of 4-dimethylaminopyridine, (DMAP) (0.0076 mol), and 50 mL of tetrahydrofuran (THF) were added into another reaction bottle, obtaining a second solution. Next, the first solution was added dropwisely into the second solution in an ice bath (0° C.). After the addition was complete, the mixture was stirred at in an ice bath (0° C.) for 30 minutes, and then stirred at room temperature (25° C.) for 1 hour. Next, after removing tetrahydrofuran (THF), 100 mL of dichloromethane (CH2Cl2) was added. After subjecting it to an ultrasonic vibration treatment for 30 minutes, 50 mL of hydrochloric acid aqueous solution (5 wt %) was mixed with the mixture. After extraction, an organic phase was separated, and then dried by anhydrous magnesium sulfate. After concentration, the result was dissolved in 10 mL of tetrahydrofuran (THF). Next, 200 mL of methanol was added, and then a solid was deposited. After removing the solid by filtration, the filtrate was collected. After concentration, Compound 4 (maroon liquid) was obtained with a yield of 56%. The synthesis pathway of the above reaction was as follows:
Next, 5.3 g of compound 4(0.015 mol), 0.6 g of pyridine, and 40 mL of dichloromethane (CH2Cl2) were added into a reaction bottle. Next, 2 g of triphosgene (dissolved in10 mL of dichloromethane) was added slowly into the reaction bottle in an ice bath (0° C.). After stirring for 1 hour, a third solution was obtained. Next, 1.5 g of compound 3(
S-form) (0.006 mol), 0.6 g of triethylamine (0.006 mol), 0.01 g of 4-dimethylaminopyridine (DMAP) (0.0006 mol), and 50 mL of tetrahydrofuran (THF) were added into another reaction bottle, obtaining a fourth solution. Next, the third solution was added dropwisely into the fourth solution in an ice bath (0° C.). After the addition was complete, the mixture was stirred in an ice bath (0° C.) for 30 minutes and then stirred at room temperature (25° C.) for 1 hour. Next, after removing tetrahydrofuran (THF), 100 mL of dichloromethane (CH2Cl2) was added. After subjecting it to an ultrasonic vibration treatment for 30 minutes, 50 mL of hydrochloric acid aqueous solution (5 wt %) was added. After extraction, an organic phase was separated, and then dried by anhydrous magnesium sulfate. After concentration, 10 mL of tetrahydrofuran (THF) was added. Next, 200 mL of methanol was added, and then a solid was deposited. After removing the solid by filtration, the filtrate was collected. After concentration, Chiral Compound 2 was obtained with a yield of 75%. The synthesis pathway of the above reaction was as follows:
Chiral Compound 2 was analyzed by nuclear magnetic resonance (NMR) spectroscopy and the result is as follows: 1H NMR (300 MHz, CDCl3): 1.95(s, 8H), 2.33-2.41(m,4H), 3.3(d, J=2.75 Hz,4H), 4.01(d, J=4.4 Hz, 4H), 4.21-4.24(d, J=5.5 Hz, 4H), 5.80-5.83(d, J=10.1 Hz, 2H), 6.11-6.16(dd, J=8.4,10.4 Hz, 2H), 6.40-6.44(d, J=17.34 Hz, 2H), 6.90-6.92(d, J=8.6 Hz, 4H),6.96-6.99(d, J=8.8 Hz, 4H), 7.00-7.02(d, J=7.9 Hz, 2H), 7.02-7.04(d, J=8.8 Hz, 4H), 7.15-7.17(d, J=8.1 Hz, 2H), 7.23-7.25(d, J=8.0 Hz, 2H), 7.97-7.98(d, J=8.5 Hz, 4H)
The helical twisting power (HTP) of Chiral Compound 1(prepared by Example 1) and Chiral Compound 2 (prepared by Example 2) were measured, and the result was shown in Table 1.
As shown in Table 1, since the compound represented by Formula (I) of the disclosure exhibits higher helical twisting power, a reduced dosage of the chiral compound can be employed by the liquid-crystal composition for achieving a predetermined pitch, resulting in reducing the driving voltage and cost of the liquid-crystal device and preventing the characteristics and phase behavior of the liquid-crystal composition from deteriorating.
1 g of compound 3(S-form) (0.004 mol), 0.4 g of triethylamine (0.076 mol), 4 g of 4-nitrophenyl chloroformate (0.02 mol), and 10 ml of tetrahydrofuran (THF) were added into a reaction bottle. After stirring at 25° C. for 48 hrs, tetrahydrofuran (THF) was removed and then 10 mL of ethyl acetate (EA) and 10 ml of water were added into the reaction bottle. After extraction, an organic phase was separated, and then dried by anhydrous magnesium sulfate. After concentration and recrystallization with tetrahydrofuran (THF) and methanol, Chiral Compound 3 was obtained with a yield of 50%. The synthesis pathway of the above reaction was as follows:
Chiral Compound 3 was analyzed by nuclear magnetic resonance (NMR) spectroscopy and the result is as follows: 1H NMR (400 MHz, CDCl3): 2.33-2.38(m,2H),2.45-2.50(m,2H),3.10-3.20(m,4H),7.08-7.10(d, J=7.2 Hz 4H), 7.13-7.15(d, J=6.4 Hz 2H), 7.18-7.20(d, J=5.6 Hz 2H), 7.25-7.27(d, J=6.0 Hz 2H), 8.17-8.19(d, J=7.2 Hz 4H)
Characteristics of liquid-crystal composition
0.01 g of Chiral Compound 1 was mixed with 4.99 g negative liquid-crystal host (Δn=0.1, Δε=−2.1, having a viscosity of 20 mPa·s), obtaining a liquid-crystal composition. The voltage holding ratio (VHR) and precipitation time under low temperature of the liquid-crystal composition were measured, and the results were shown in Table 2.
As shown in Table 2, the liquid-crystal composition employing the compound of the disclosure exhibits high voltage holding ratio (≥95%), resulting in improving the image contrast and reducing the image sticking of the active matrix liquid-crystal display device employing the liquid-crystal composition. Furthermore, the compound of the disclosure has long precipitation time under low temperature (such as −25° C. or −40° C.).
Solubility (wt %)
Chiral Compound 1 and Chiral Compound 2 were mixed with the liquid-crystal host (with a trade No. of IBL-087) individually for measuring the maximum additive weight percentage of Chiral Compound 1 (or Chiral Compound 2), wherein the maximum additive concentration was determined by whether the Chiral Compound was precipitated on the sidewall of the bottle. The results are shown in Table 3.
As shown in Table 3, the compound of the disclosure has high solubility (>15 wt %) in the liquid-crystal host.
It will be clear that various modifications and variations can be made to the disclosed methods and materials. It is intended that the specification and examples be considered as exemplary only, with the true scope of the disclosure being indicated by the following claims and their equivalents.
This application is a Continuation-In-Part of pending U.S. patent application Ser. No. 14/976,947, filed Dec. 21, 2015 and entitled “compound and liquid-crystal composition employing the same”, the entirety of which is incorporated by reference herein.
| Number | Name | Date | Kind |
|---|---|---|---|
| 622056 | Marshall | Mar 1899 | A |
| 3945968 | Goletto | Mar 1976 | A |
| 4346167 | Imatomi et al. | Aug 1982 | A |
| 4895793 | Seto et al. | Jan 1990 | A |
| 5024850 | Broer et al. | Jun 1991 | A |
| 5053555 | Yeager et al. | Oct 1991 | A |
| 5744057 | Meyer et al. | Apr 1998 | A |
| 7052743 | Welter et al. | May 2006 | B2 |
| 7150900 | Welter | Dec 2006 | B2 |
| 7329368 | Welter | Feb 2008 | B2 |
| 7452482 | Welter | Nov 2008 | B2 |
| 7470376 | Welter et al. | Dec 2008 | B2 |
| 7820251 | Chen et al. | Oct 2010 | B2 |
| 8023080 | Kuo et al. | Sep 2011 | B2 |
| 8449953 | Cheng et al. | May 2013 | B2 |
| 8460766 | Huang et al. | Jun 2013 | B2 |
| 8715528 | Chen et al. | May 2014 | B2 |
| 8906472 | Kuriyama et al. | Dec 2014 | B2 |
| 20050072961 | Welter et al. | Apr 2005 | A1 |
| 20120289731 | Chen et al. | Nov 2012 | A1 |
| 20140022473 | Goetz et al. | Jan 2014 | A1 |
| 20140256896 | Nakata et al. | Sep 2014 | A1 |
| Number | Date | Country |
|---|---|---|
| I271431IB | Jan 2007 | TW |
| 201245422 | Nov 2012 | TW |
| I410424 | Oct 2013 | TW |
| I414527 | Nov 2013 | TW |
| I443180 | Jul 2014 | TW |
| I480635 | Apr 2015 | TW |
| Entry |
|---|
| Hsieh et al., “Preparation and Characterization of Polymer Stabilized Liquid Crystal cells with Chiral compounds derived from Camphor,” 2007 International Symposium on Nano Science and Technology, Tainan, Taiwan, Nov. 8-9, 2007, 2 pages. |
| Sen et al, “Spiro-biindane containing fluorinated poly(ether imide)s: Synthesis, characterization and gas separation properties,” Journal of Membrane Science, vol. 365, 2010, (Available Online Sep. 25, 2010), pp. 329-340. |
| Stenzel et al., “Bis(2,4,7-trimethylindenyl)cobalt(II) and rac-2,2′,4,4′,7,7′-hexamethyl-1,1′-biindene,” Acta Crystallographica, Section C, C57, 2001, pp. 1056-1059. |
| Taiwanese Office Action and Search Report for Taiwanese Application No. 104143092, dated Jul. 22, 2016. |
| Number | Date | Country | |
|---|---|---|---|
| 20170174995 A1 | Jun 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14976947 | Dec 2015 | US |
| Child | 15333583 | US |
